Working… Menu

Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01601119
Recruitment Status : Completed
First Posted : May 17, 2012
Last Update Posted : May 29, 2015
Merck Serono Limited, UK
Information provided by (Responsible Party):
Merck KGaA, Darmstadt, Germany

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : July 2014
Actual Study Completion Date : July 2014